vivelle dot forðaplástur 37,5 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 37,5 míkróg
vivelle dot forðaplástur 50 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 50 míkróg
vivelle dot forðaplástur 75 míkróg
sandoz a/s - estradiolum inn - forðaplástur - 75 míkróg
ibuprofen zentiva filmuhúðuð tafla 600 mg
zentiva k.s.* - ibuprofenum inn - filmuhúðuð tafla - 600 mg
rewellfem leggangatafla 10 míkróg
gedeon richter plc.* - estradiolum inn - leggangatafla - 10 míkróg
dexamethasone hameln stungulyf, lausn 4 mg/ml
hameln pharma gmbh - dexamethasonum natríumfosfat - stungulyf, lausn - 4 mg/ml
ibetin filmuhúðuð tafla 400 mg
zentiva k.s.* - ibuprofenum inn - filmuhúðuð tafla - 400 mg
ibuprofen zentiva filmuhúðuð tafla 400 mg
zentiva k.s.* - ibuprofenum inn - filmuhúðuð tafla - 400 mg
litak
lipomed gmbh - kladríbíni - hvítblæði, hairy cell - Æxlishemjandi lyf - litak er ætlað til meðferðar á hvítum frumu hvítblæði.
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lyf til að meðhöndla beinsjúkdóma - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.